Study identification

EU PAS number

EUPAS49988

Study ID

49989

Official title and acronym

Predicting Long-Term Outcome Risk with Tirzepatide: A Post-Hoc Analysis of SURMOUNT-1

DARWIN EU® study

No

Study countries

United States

Study description

This study will evaluate the change in predicted risk for cardiovascular disease and type 2 diabetes between tirzepatide and placebo-treated participants using the SURMOUNT-1 trial data at baseline and 72 weeks. SURMOUNT-1 was a phase 3 trial in adults with overweight or obesity evaluating the impact of tirzepatide versus placebo on weight loss and associated endpoints. The predicted risk will be calculated using validated risk engines.

Study status

Planned
Research institutions and networks

Institutions

Contact details

Lilly Value Evidence and Outcomes

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable